Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Camidge on Biomarker Combinations in NSCLC

August 10th 2018

David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses biomarker combinations in non–small cell lung cancer (NSCLC).

Dr. Herbst on Key Immunotherapy Findings in NSCLC

August 10th 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses key immunotherapy findings in non–small cell lung cancer, presented at the 2018 ASCO Annual Meeting.

Molecular Testing: Future Directions in NSCLC

August 10th 2018

Selecting a Molecular Panel in NSCLC

August 10th 2018

NSCLC: Use of TMB in CheckMate-227

August 10th 2018

NSCLC: Increasing the Value of Molecular Testing

August 10th 2018

Understanding the Molecular Targets of NSCLC

August 10th 2018

Optimizing Molecular Testing Methods in NSCLC

August 10th 2018

NSCLC: Challenges With PD-L1 as Biomarker

August 10th 2018

Evaluating the Role of Molecular Analysis in NSCLC

August 10th 2018

Molecular Testing Through Multiple Labs in NSCLC

August 10th 2018

Adequate Tissue Collection for Molecular Testing in NSCLC

August 10th 2018

Communicating Goals of Molecular Testing in NSCLC

August 10th 2018

Evolution of Biopsy for NSCLC

August 10th 2018

Dr. Menter on Neoadjuvant Immunotherapy in Early-Stage NSCLC

August 10th 2018

Alexander R. Menter, MD, oncologist, Kaiser Permanente, discusses the use of neoadjuvant immunotherapy in patients with early-stage non–small cell lung cancer (NSCLC).

Dr. Aisner on the Limitations of Molecular Profiling

August 10th 2018

Dara L. Aisner, MD, PhD, associate professor in the department of Pathology at the University of Colorado School of Medicine, discusses the limitations of molecular profiling.

Expert Explains Limitations of Molecular Profiling in Lung Cancer

August 10th 2018

Dara L. Aisner, MD, PhD, discusses the rapidly progressing field of molecular profiling, the importance of understanding assay results, and how they translate to patient care in lung cancer.

Dr. Wistuba on Biomarkers for Immunotherapy in Lung Cancer

August 8th 2018

Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Medicine, The University of Texas MD Anderson Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

FDA Grants Lurbinectedin Orphan Drug Status for SCLC

August 7th 2018

The FDA has granted lurbinectedin (PM1183) an orphan drug designation for the treatment of patients with small cell lung cancer.

Borghaei Discusses Nivolumab/Ipilimumab CheckMate-227 NSCLC Findings

August 6th 2018

Hossein Borghaei, DO, MS, discusses the results of the subgroup analysis of the ongoing CheckMate-227 trial in metastatic non–small cell lung cancer.